NCT00779779View on ClinicalTrials.gov

Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants

CompletedOBSERVATIONAL
Enrollment

522

Participants

Timeline

Start Date

November 22, 2008

Primary Completion Date

May 25, 2009

Study Completion Date

August 26, 2009

Conditions
Infections, Rotavirus
Interventions
BIOLOGICAL

Rotarix™

Two oral doses, with at least 4 weeks interval in-between

Trial Locations (1)

03

GSK Investigational Site, Colombo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY